nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluorouracil—urinary bladder cancer—testicular cancer	0.511	1	CtDrD
Fluorouracil—ABCC5—Cisplatin—testicular cancer	0.0412	0.117	CbGbCtD
Fluorouracil—MTHFR—Methotrexate—testicular cancer	0.0381	0.108	CbGbCtD
Fluorouracil—TYMS—Methotrexate—testicular cancer	0.0324	0.0923	CbGbCtD
Fluorouracil—ABCC3—Cisplatin—testicular cancer	0.0259	0.0737	CbGbCtD
Fluorouracil—ABCC3—Etoposide—testicular cancer	0.0254	0.0724	CbGbCtD
Fluorouracil—CYP2A6—Ifosfamide—testicular cancer	0.0236	0.0673	CbGbCtD
Fluorouracil—ABCG2—Dactinomycin—testicular cancer	0.0185	0.0527	CbGbCtD
Fluorouracil—ABCC3—Doxorubicin—testicular cancer	0.0174	0.0494	CbGbCtD
Fluorouracil—ABCC3—Methotrexate—testicular cancer	0.0168	0.0479	CbGbCtD
Fluorouracil—SLC22A7—Methotrexate—testicular cancer	0.0131	0.0374	CbGbCtD
Fluorouracil—ABCC4—Methotrexate—testicular cancer	0.0128	0.0366	CbGbCtD
Fluorouracil—ABCG2—Carboplatin—testicular cancer	0.0125	0.0354	CbGbCtD
Fluorouracil—CYP2C8—Ifosfamide—testicular cancer	0.0117	0.0332	CbGbCtD
Fluorouracil—ABCG2—Cisplatin—testicular cancer	0.0106	0.0303	CbGbCtD
Fluorouracil—ABCG2—Etoposide—testicular cancer	0.0105	0.0298	CbGbCtD
Fluorouracil—CYP2C9—Ifosfamide—testicular cancer	0.00813	0.0231	CbGbCtD
Fluorouracil—ABCG2—Doxorubicin—testicular cancer	0.00713	0.0203	CbGbCtD
Fluorouracil—ABCG2—Methotrexate—testicular cancer	0.00691	0.0197	CbGbCtD
Fluorouracil—CYP2C8—Etoposide—testicular cancer	0.00557	0.0159	CbGbCtD
Fluorouracil—ALB—Methotrexate—testicular cancer	0.00476	0.0136	CbGbCtD
Fluorouracil—CYP1A2—Etoposide—testicular cancer	0.00431	0.0123	CbGbCtD
Fluorouracil—CYP2C9—Cisplatin—testicular cancer	0.00395	0.0113	CbGbCtD
Fluorouracil—UPP1—seminal vesicle—testicular cancer	0.00227	0.0714	CbGeAlD
Fluorouracil—PPAT—seminal vesicle—testicular cancer	0.0016	0.0502	CbGeAlD
Fluorouracil—UMPS—female gonad—testicular cancer	0.00145	0.0457	CbGeAlD
Fluorouracil—UPP1—female gonad—testicular cancer	0.00133	0.0419	CbGeAlD
Fluorouracil—UMPS—testis—testicular cancer	0.00129	0.0406	CbGeAlD
Fluorouracil—UPP1—testis—testicular cancer	0.00118	0.0372	CbGeAlD
Fluorouracil—PPAT—gonad—testicular cancer	0.00115	0.0363	CbGeAlD
Fluorouracil—DPYD—female gonad—testicular cancer	0.00108	0.0341	CbGeAlD
Fluorouracil—TYMP—seminal vesicle—testicular cancer	0.00107	0.0336	CbGeAlD
Fluorouracil—DPYD—testis—testicular cancer	0.00096	0.0302	CbGeAlD
Fluorouracil—PPAT—female gonad—testicular cancer	0.000937	0.0295	CbGeAlD
Fluorouracil—UMPS—lymph node—testicular cancer	0.000935	0.0294	CbGeAlD
Fluorouracil—UPP1—lymph node—testicular cancer	0.000857	0.027	CbGeAlD
Fluorouracil—PPAT—testis—testicular cancer	0.000831	0.0261	CbGeAlD
Fluorouracil—CYP2A6—seminal vesicle—testicular cancer	0.000802	0.0252	CbGeAlD
Fluorouracil—DPYD—lymph node—testicular cancer	0.000696	0.0219	CbGeAlD
Fluorouracil—TYMS—gonad—testicular cancer	0.000662	0.0208	CbGeAlD
Fluorouracil—TYMP—female gonad—testicular cancer	0.000627	0.0197	CbGeAlD
Fluorouracil—PPAT—lymph node—testicular cancer	0.000602	0.0189	CbGeAlD
Fluorouracil—SLC29A1—gonad—testicular cancer	0.000594	0.0187	CbGeAlD
Fluorouracil—MTHFR—female gonad—testicular cancer	0.00059	0.0186	CbGeAlD
Fluorouracil—TYMP—testis—testicular cancer	0.000556	0.0175	CbGeAlD
Fluorouracil—SLC22A7—testis—testicular cancer	0.000555	0.0174	CbGeAlD
Fluorouracil—TYMS—female gonad—testicular cancer	0.000538	0.0169	CbGeAlD
Fluorouracil—ABCC5—female gonad—testicular cancer	0.000526	0.0165	CbGeAlD
Fluorouracil—MTHFR—testis—testicular cancer	0.000523	0.0165	CbGeAlD
Fluorouracil—SLC29A1—female gonad—testicular cancer	0.000483	0.0152	CbGeAlD
Fluorouracil—TYMS—testis—testicular cancer	0.000477	0.015	CbGeAlD
Fluorouracil—ABCC5—testis—testicular cancer	0.000466	0.0147	CbGeAlD
Fluorouracil—ABCC3—female gonad—testicular cancer	0.000441	0.0139	CbGeAlD
Fluorouracil—ABCG2—seminal vesicle—testicular cancer	0.000438	0.0138	CbGeAlD
Fluorouracil—SLC29A1—testis—testicular cancer	0.000428	0.0135	CbGeAlD
Fluorouracil—TYMP—lymph node—testicular cancer	0.000403	0.0127	CbGeAlD
Fluorouracil—ABCC3—testis—testicular cancer	0.000391	0.0123	CbGeAlD
Fluorouracil—MTHFR—lymph node—testicular cancer	0.000379	0.0119	CbGeAlD
Fluorouracil—ABCC4—female gonad—testicular cancer	0.000364	0.0115	CbGeAlD
Fluorouracil—TYMS—lymph node—testicular cancer	0.000346	0.0109	CbGeAlD
Fluorouracil—UMPS—Idarubicin—Epirubicin—testicular cancer	0.000345	0.14	CbGdCrCtD
Fluorouracil—UMPS—Doxorubicin—Epirubicin—testicular cancer	0.000345	0.14	CbGdCrCtD
Fluorouracil—UMPS—Daunorubicin—Epirubicin—testicular cancer	0.000345	0.14	CbGdCrCtD
Fluorouracil—ABCC5—lymph node—testicular cancer	0.000338	0.0106	CbGeAlD
Fluorouracil—ALB—testis—testicular cancer	0.000334	0.0105	CbGeAlD
Fluorouracil—ABCC4—testis—testicular cancer	0.000323	0.0102	CbGeAlD
Fluorouracil—UMPS—Epirubicin—Doxorubicin—testicular cancer	0.000319	0.129	CbGdCrCtD
Fluorouracil—UMPS—Idarubicin—Doxorubicin—testicular cancer	0.000319	0.129	CbGdCrCtD
Fluorouracil—UMPS—Daunorubicin—Doxorubicin—testicular cancer	0.000319	0.129	CbGdCrCtD
Fluorouracil—SLC29A1—lymph node—testicular cancer	0.00031	0.00976	CbGeAlD
Fluorouracil—ABCC3—lymph node—testicular cancer	0.000284	0.00893	CbGeAlD
Fluorouracil—ABCG2—female gonad—testicular cancer	0.000257	0.00809	CbGeAlD
Fluorouracil—ALB—lymph node—testicular cancer	0.000242	0.00761	CbGeAlD
Fluorouracil—CYP2C8—testis—testicular cancer	0.000235	0.00738	CbGeAlD
Fluorouracil—ABCC4—lymph node—testicular cancer	0.000234	0.00737	CbGeAlD
Fluorouracil—ABCG2—testis—testicular cancer	0.000228	0.00718	CbGeAlD
Fluorouracil—MTHFR—Trans-sulfuration and one carbon metabolism—DNMT3L—testicular cancer	0.000181	0.145	CbGpPWpGaD
Fluorouracil—TYMS—Vinorelbine—Vinblastine—testicular cancer	0.000166	0.0672	CbGdCrCtD
Fluorouracil—TYMS—Podofilox—Etoposide—testicular cancer	0.000166	0.0671	CbGdCrCtD
Fluorouracil—ABCG2—lymph node—testicular cancer	0.000165	0.0052	CbGeAlD
Fluorouracil—TYMS—Vincristine—Vinblastine—testicular cancer	0.000142	0.0574	CbGdCrCtD
Fluorouracil—TYMS—Trans-sulfuration and one carbon metabolism—DNMT3L—testicular cancer	0.00014	0.112	CbGpPWpGaD
Fluorouracil—Tachycardia—Cisplatin—testicular cancer	7.63e-05	0.000743	CcSEcCtD
Fluorouracil—Convulsion—Etoposide—testicular cancer	7.6e-05	0.00074	CcSEcCtD
Fluorouracil—Osteoarthritis—Doxorubicin—testicular cancer	7.56e-05	0.000736	CcSEcCtD
Fluorouracil—Gastrointestinal haemorrhage—Doxorubicin—testicular cancer	7.56e-05	0.000736	CcSEcCtD
Fluorouracil—Pruritus—Bleomycin—testicular cancer	7.5e-05	0.000731	CcSEcCtD
Fluorouracil—Dry skin—Epirubicin—testicular cancer	7.48e-05	0.000729	CcSEcCtD
Fluorouracil—Feeling abnormal—Ifosfamide—testicular cancer	7.47e-05	0.000727	CcSEcCtD
Fluorouracil—Chest pain—Etoposide—testicular cancer	7.47e-05	0.000727	CcSEcCtD
Fluorouracil—Eosinophilia—Methotrexate—testicular cancer	7.47e-05	0.000727	CcSEcCtD
Fluorouracil—Nausea—Vinblastine—testicular cancer	7.46e-05	0.000726	CcSEcCtD
Fluorouracil—Anorexia—Cisplatin—testicular cancer	7.45e-05	0.000725	CcSEcCtD
Fluorouracil—Discomfort—Etoposide—testicular cancer	7.38e-05	0.000718	CcSEcCtD
Fluorouracil—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	7.36e-05	0.0589	CbGpPWpGaD
Fluorouracil—Hypotension—Cisplatin—testicular cancer	7.3e-05	0.000711	CcSEcCtD
Fluorouracil—Nasopharyngitis—Epirubicin—testicular cancer	7.3e-05	0.000711	CcSEcCtD
Fluorouracil—Hypersensitivity—Dactinomycin—testicular cancer	7.29e-05	0.00071	CcSEcCtD
Fluorouracil—Confusional state—Etoposide—testicular cancer	7.22e-05	0.000703	CcSEcCtD
Fluorouracil—Muscular weakness—Epirubicin—testicular cancer	7.2e-05	0.000701	CcSEcCtD
Fluorouracil—Urticaria—Ifosfamide—testicular cancer	7.2e-05	0.000701	CcSEcCtD
Fluorouracil—Cardiac arrest—Doxorubicin—testicular cancer	7.18e-05	0.000699	CcSEcCtD
Fluorouracil—Body temperature increased—Ifosfamide—testicular cancer	7.17e-05	0.000698	CcSEcCtD
Fluorouracil—Pancytopenia—Methotrexate—testicular cancer	7.16e-05	0.000697	CcSEcCtD
Fluorouracil—Anaphylactic shock—Etoposide—testicular cancer	7.16e-05	0.000697	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Cisplatin—testicular cancer	7.12e-05	0.000693	CcSEcCtD
Fluorouracil—Infection—Etoposide—testicular cancer	7.11e-05	0.000693	CcSEcCtD
Fluorouracil—Ataxia—Doxorubicin—testicular cancer	7.1e-05	0.000692	CcSEcCtD
Fluorouracil—Dysphagia—Epirubicin—testicular cancer	7.06e-05	0.000687	CcSEcCtD
Fluorouracil—Paraesthesia—Cisplatin—testicular cancer	7.02e-05	0.000683	CcSEcCtD
Fluorouracil—Thrombocytopenia—Etoposide—testicular cancer	7.01e-05	0.000683	CcSEcCtD
Fluorouracil—Upper respiratory tract infection—Methotrexate—testicular cancer	7.01e-05	0.000682	CcSEcCtD
Fluorouracil—Tachycardia—Etoposide—testicular cancer	6.99e-05	0.00068	CcSEcCtD
Fluorouracil—Eosinophilia—Epirubicin—testicular cancer	6.99e-05	0.00068	CcSEcCtD
Fluorouracil—Dyspnoea—Cisplatin—testicular cancer	6.97e-05	0.000678	CcSEcCtD
Fluorouracil—Dry skin—Doxorubicin—testicular cancer	6.93e-05	0.000674	CcSEcCtD
Fluorouracil—Photosensitivity reaction—Methotrexate—testicular cancer	6.88e-05	0.00067	CcSEcCtD
Fluorouracil—Angina pectoris—Epirubicin—testicular cancer	6.87e-05	0.000669	CcSEcCtD
Fluorouracil—Anorexia—Etoposide—testicular cancer	6.82e-05	0.000664	CcSEcCtD
Fluorouracil—Decreased appetite—Cisplatin—testicular cancer	6.79e-05	0.000661	CcSEcCtD
Fluorouracil—Diarrhoea—Dactinomycin—testicular cancer	6.77e-05	0.000659	CcSEcCtD
Fluorouracil—Pneumonia—Methotrexate—testicular cancer	6.76e-05	0.000658	CcSEcCtD
Fluorouracil—Nasopharyngitis—Doxorubicin—testicular cancer	6.76e-05	0.000658	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Cisplatin—testicular cancer	6.75e-05	0.000657	CcSEcCtD
Fluorouracil—Vomiting—Bleomycin—testicular cancer	6.74e-05	0.000657	CcSEcCtD
Fluorouracil—TYMP—Bladder Cancer—FGFR3—testicular cancer	6.73e-05	0.0539	CbGpPWpGaD
Fluorouracil—Infestation—Methotrexate—testicular cancer	6.72e-05	0.000655	CcSEcCtD
Fluorouracil—Infestation NOS—Methotrexate—testicular cancer	6.72e-05	0.000655	CcSEcCtD
Fluorouracil—Pancytopenia—Epirubicin—testicular cancer	6.7e-05	0.000653	CcSEcCtD
Fluorouracil—Hypotension—Etoposide—testicular cancer	6.69e-05	0.000651	CcSEcCtD
Fluorouracil—Rash—Bleomycin—testicular cancer	6.69e-05	0.000651	CcSEcCtD
Fluorouracil—Pain—Cisplatin—testicular cancer	6.68e-05	0.000651	CcSEcCtD
Fluorouracil—Dermatitis—Bleomycin—testicular cancer	6.68e-05	0.000651	CcSEcCtD
Fluorouracil—Hypersensitivity—Ifosfamide—testicular cancer	6.68e-05	0.00065	CcSEcCtD
Fluorouracil—Muscular weakness—Doxorubicin—testicular cancer	6.66e-05	0.000649	CcSEcCtD
Fluorouracil—Upper respiratory tract infection—Epirubicin—testicular cancer	6.56e-05	0.000639	CcSEcCtD
Fluorouracil—Stomatitis—Methotrexate—testicular cancer	6.55e-05	0.000638	CcSEcCtD
Fluorouracil—Conjunctivitis—Methotrexate—testicular cancer	6.54e-05	0.000636	CcSEcCtD
Fluorouracil—Dysphagia—Doxorubicin—testicular cancer	6.53e-05	0.000636	CcSEcCtD
Fluorouracil—Eosinophilia—Doxorubicin—testicular cancer	6.47e-05	0.00063	CcSEcCtD
Fluorouracil—Photosensitivity reaction—Epirubicin—testicular cancer	6.44e-05	0.000627	CcSEcCtD
Fluorouracil—Feeling abnormal—Cisplatin—testicular cancer	6.44e-05	0.000627	CcSEcCtD
Fluorouracil—Paraesthesia—Etoposide—testicular cancer	6.43e-05	0.000626	CcSEcCtD
Fluorouracil—Pruritus—Ifosfamide—testicular cancer	6.41e-05	0.000624	CcSEcCtD
Fluorouracil—Dyspnoea—Etoposide—testicular cancer	6.38e-05	0.000621	CcSEcCtD
Fluorouracil—Somnolence—Etoposide—testicular cancer	6.36e-05	0.00062	CcSEcCtD
Fluorouracil—Angina pectoris—Doxorubicin—testicular cancer	6.36e-05	0.000619	CcSEcCtD
Fluorouracil—Epistaxis—Methotrexate—testicular cancer	6.34e-05	0.000618	CcSEcCtD
Fluorouracil—Pneumonia—Epirubicin—testicular cancer	6.33e-05	0.000616	CcSEcCtD
Fluorouracil—Nausea—Bleomycin—testicular cancer	6.3e-05	0.000613	CcSEcCtD
Fluorouracil—Infestation NOS—Epirubicin—testicular cancer	6.29e-05	0.000613	CcSEcCtD
Fluorouracil—Infestation—Epirubicin—testicular cancer	6.29e-05	0.000613	CcSEcCtD
Fluorouracil—Vomiting—Dactinomycin—testicular cancer	6.29e-05	0.000612	CcSEcCtD
Fluorouracil—Agranulocytosis—Methotrexate—testicular cancer	6.27e-05	0.000611	CcSEcCtD
Fluorouracil—Rash—Dactinomycin—testicular cancer	6.24e-05	0.000607	CcSEcCtD
Fluorouracil—Decreased appetite—Etoposide—testicular cancer	6.22e-05	0.000606	CcSEcCtD
Fluorouracil—Diarrhoea—Ifosfamide—testicular cancer	6.2e-05	0.000604	CcSEcCtD
Fluorouracil—Pancytopenia—Doxorubicin—testicular cancer	6.2e-05	0.000604	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Etoposide—testicular cancer	6.18e-05	0.000602	CcSEcCtD
Fluorouracil—Body temperature increased—Cisplatin—testicular cancer	6.18e-05	0.000602	CcSEcCtD
Fluorouracil—Neuropathy peripheral—Epirubicin—testicular cancer	6.17e-05	0.000601	CcSEcCtD
Fluorouracil—ABCC5—NRF2 pathway—SLC2A6—testicular cancer	6.17e-05	0.0494	CbGpPWpGaD
Fluorouracil—Stomatitis—Epirubicin—testicular cancer	6.13e-05	0.000597	CcSEcCtD
Fluorouracil—Pain—Etoposide—testicular cancer	6.12e-05	0.000596	CcSEcCtD
Fluorouracil—Conjunctivitis—Epirubicin—testicular cancer	6.12e-05	0.000596	CcSEcCtD
Fluorouracil—Urinary tract infection—Epirubicin—testicular cancer	6.12e-05	0.000596	CcSEcCtD
Fluorouracil—Upper respiratory tract infection—Doxorubicin—testicular cancer	6.07e-05	0.000591	CcSEcCtD
Fluorouracil—Haemoglobin—Methotrexate—testicular cancer	6.07e-05	0.000591	CcSEcCtD
Fluorouracil—Haemorrhage—Methotrexate—testicular cancer	6.04e-05	0.000588	CcSEcCtD
Fluorouracil—Dizziness—Ifosfamide—testicular cancer	5.99e-05	0.000584	CcSEcCtD
Fluorouracil—Pharyngitis—Methotrexate—testicular cancer	5.99e-05	0.000583	CcSEcCtD
Fluorouracil—Photosensitivity reaction—Doxorubicin—testicular cancer	5.96e-05	0.00058	CcSEcCtD
Fluorouracil—Epistaxis—Epirubicin—testicular cancer	5.94e-05	0.000578	CcSEcCtD
Fluorouracil—Sinusitis—Epirubicin—testicular cancer	5.9e-05	0.000575	CcSEcCtD
Fluorouracil—Feeling abnormal—Etoposide—testicular cancer	5.9e-05	0.000574	CcSEcCtD
Fluorouracil—Nausea—Dactinomycin—testicular cancer	5.88e-05	0.000572	CcSEcCtD
Fluorouracil—Agranulocytosis—Epirubicin—testicular cancer	5.87e-05	0.000572	CcSEcCtD
Fluorouracil—SLC29A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	5.87e-05	0.047	CbGpPWpGaD
Fluorouracil—Pneumonia—Doxorubicin—testicular cancer	5.86e-05	0.00057	CcSEcCtD
Fluorouracil—Infestation NOS—Doxorubicin—testicular cancer	5.82e-05	0.000567	CcSEcCtD
Fluorouracil—Infestation—Doxorubicin—testicular cancer	5.82e-05	0.000567	CcSEcCtD
Fluorouracil—Vomiting—Ifosfamide—testicular cancer	5.76e-05	0.000561	CcSEcCtD
Fluorouracil—Hypersensitivity—Cisplatin—testicular cancer	5.76e-05	0.000561	CcSEcCtD
Fluorouracil—Rash—Ifosfamide—testicular cancer	5.72e-05	0.000557	CcSEcCtD
Fluorouracil—Dermatitis—Ifosfamide—testicular cancer	5.71e-05	0.000556	CcSEcCtD
Fluorouracil—Neuropathy peripheral—Doxorubicin—testicular cancer	5.71e-05	0.000556	CcSEcCtD
Fluorouracil—Urticaria—Etoposide—testicular cancer	5.69e-05	0.000554	CcSEcCtD
Fluorouracil—Haemoglobin—Epirubicin—testicular cancer	5.68e-05	0.000553	CcSEcCtD
Fluorouracil—Stomatitis—Doxorubicin—testicular cancer	5.68e-05	0.000553	CcSEcCtD
Fluorouracil—Rhinitis—Epirubicin—testicular cancer	5.66e-05	0.000551	CcSEcCtD
Fluorouracil—Body temperature increased—Etoposide—testicular cancer	5.66e-05	0.000551	CcSEcCtD
Fluorouracil—Urinary tract infection—Doxorubicin—testicular cancer	5.66e-05	0.000551	CcSEcCtD
Fluorouracil—Conjunctivitis—Doxorubicin—testicular cancer	5.66e-05	0.000551	CcSEcCtD
Fluorouracil—Haemorrhage—Epirubicin—testicular cancer	5.65e-05	0.00055	CcSEcCtD
Fluorouracil—Hypoaesthesia—Epirubicin—testicular cancer	5.62e-05	0.000547	CcSEcCtD
Fluorouracil—Pharyngitis—Epirubicin—testicular cancer	5.61e-05	0.000546	CcSEcCtD
Fluorouracil—Epistaxis—Doxorubicin—testicular cancer	5.49e-05	0.000535	CcSEcCtD
Fluorouracil—Sinusitis—Doxorubicin—testicular cancer	5.46e-05	0.000532	CcSEcCtD
Fluorouracil—Agranulocytosis—Doxorubicin—testicular cancer	5.43e-05	0.000529	CcSEcCtD
Fluorouracil—Nausea—Ifosfamide—testicular cancer	5.38e-05	0.000524	CcSEcCtD
Fluorouracil—Diarrhoea—Cisplatin—testicular cancer	5.35e-05	0.000521	CcSEcCtD
Fluorouracil—Alopecia—Methotrexate—testicular cancer	5.33e-05	0.000519	CcSEcCtD
Fluorouracil—Hypersensitivity—Etoposide—testicular cancer	5.27e-05	0.000514	CcSEcCtD
Fluorouracil—Erythema—Methotrexate—testicular cancer	5.25e-05	0.000512	CcSEcCtD
Fluorouracil—Haemoglobin—Doxorubicin—testicular cancer	5.25e-05	0.000511	CcSEcCtD
Fluorouracil—Rhinitis—Doxorubicin—testicular cancer	5.24e-05	0.00051	CcSEcCtD
Fluorouracil—Haemorrhage—Doxorubicin—testicular cancer	5.23e-05	0.000509	CcSEcCtD
Fluorouracil—Hypoaesthesia—Doxorubicin—testicular cancer	5.2e-05	0.000506	CcSEcCtD
Fluorouracil—Pharyngitis—Doxorubicin—testicular cancer	5.19e-05	0.000505	CcSEcCtD
Fluorouracil—Pruritus—Etoposide—testicular cancer	5.07e-05	0.000493	CcSEcCtD
Fluorouracil—Arrhythmia—Epirubicin—testicular cancer	5.05e-05	0.000491	CcSEcCtD
Fluorouracil—Alopecia—Epirubicin—testicular cancer	4.99e-05	0.000486	CcSEcCtD
Fluorouracil—Vomiting—Cisplatin—testicular cancer	4.97e-05	0.000484	CcSEcCtD
Fluorouracil—Vision blurred—Methotrexate—testicular cancer	4.95e-05	0.000482	CcSEcCtD
Fluorouracil—Rash—Cisplatin—testicular cancer	4.93e-05	0.00048	CcSEcCtD
Fluorouracil—Dermatitis—Cisplatin—testicular cancer	4.92e-05	0.000479	CcSEcCtD
Fluorouracil—Erythema—Epirubicin—testicular cancer	4.92e-05	0.000479	CcSEcCtD
Fluorouracil—Diarrhoea—Etoposide—testicular cancer	4.9e-05	0.000477	CcSEcCtD
Fluorouracil—ABCC4—Ectoderm Differentiation—TFAP2C—testicular cancer	4.89e-05	0.0392	CbGpPWpGaD
Fluorouracil—Anaemia—Methotrexate—testicular cancer	4.86e-05	0.000473	CcSEcCtD
Fluorouracil—Dizziness—Etoposide—testicular cancer	4.73e-05	0.000461	CcSEcCtD
Fluorouracil—Leukopenia—Methotrexate—testicular cancer	4.7e-05	0.000458	CcSEcCtD
Fluorouracil—Arrhythmia—Doxorubicin—testicular cancer	4.67e-05	0.000455	CcSEcCtD
Fluorouracil—Nausea—Cisplatin—testicular cancer	4.64e-05	0.000452	CcSEcCtD
Fluorouracil—Vision blurred—Epirubicin—testicular cancer	4.63e-05	0.000451	CcSEcCtD
Fluorouracil—Alopecia—Doxorubicin—testicular cancer	4.62e-05	0.00045	CcSEcCtD
Fluorouracil—Convulsion—Methotrexate—testicular cancer	4.55e-05	0.000443	CcSEcCtD
Fluorouracil—Vomiting—Etoposide—testicular cancer	4.55e-05	0.000443	CcSEcCtD
Fluorouracil—Erythema—Doxorubicin—testicular cancer	4.55e-05	0.000443	CcSEcCtD
Fluorouracil—ABCC3—NRF2 pathway—SLC2A6—testicular cancer	4.55e-05	0.0364	CbGpPWpGaD
Fluorouracil—Anaemia—Epirubicin—testicular cancer	4.54e-05	0.000443	CcSEcCtD
Fluorouracil—Rash—Etoposide—testicular cancer	4.51e-05	0.00044	CcSEcCtD
Fluorouracil—Dermatitis—Etoposide—testicular cancer	4.51e-05	0.000439	CcSEcCtD
Fluorouracil—Headache—Etoposide—testicular cancer	4.49e-05	0.000437	CcSEcCtD
Fluorouracil—Myalgia—Methotrexate—testicular cancer	4.47e-05	0.000436	CcSEcCtD
Fluorouracil—Chest pain—Methotrexate—testicular cancer	4.47e-05	0.000436	CcSEcCtD
Fluorouracil—Discomfort—Methotrexate—testicular cancer	4.42e-05	0.00043	CcSEcCtD
Fluorouracil—Leukopenia—Epirubicin—testicular cancer	4.4e-05	0.000429	CcSEcCtD
Fluorouracil—Confusional state—Methotrexate—testicular cancer	4.32e-05	0.000421	CcSEcCtD
Fluorouracil—Anaphylactic shock—Methotrexate—testicular cancer	4.29e-05	0.000418	CcSEcCtD
Fluorouracil—Vision blurred—Doxorubicin—testicular cancer	4.29e-05	0.000418	CcSEcCtD
Fluorouracil—ABCC4—NRF2 pathway—SLC2A6—testicular cancer	4.27e-05	0.0342	CbGpPWpGaD
Fluorouracil—Convulsion—Epirubicin—testicular cancer	4.26e-05	0.000415	CcSEcCtD
Fluorouracil—Infection—Methotrexate—testicular cancer	4.26e-05	0.000415	CcSEcCtD
Fluorouracil—Nausea—Etoposide—testicular cancer	4.25e-05	0.000414	CcSEcCtD
Fluorouracil—Nervous system disorder—Methotrexate—testicular cancer	4.21e-05	0.000409	CcSEcCtD
Fluorouracil—Anaemia—Doxorubicin—testicular cancer	4.21e-05	0.000409	CcSEcCtD
Fluorouracil—Thrombocytopenia—Methotrexate—testicular cancer	4.2e-05	0.000409	CcSEcCtD
Fluorouracil—Chest pain—Epirubicin—testicular cancer	4.19e-05	0.000408	CcSEcCtD
Fluorouracil—Myalgia—Epirubicin—testicular cancer	4.19e-05	0.000408	CcSEcCtD
Fluorouracil—Discomfort—Epirubicin—testicular cancer	4.14e-05	0.000403	CcSEcCtD
Fluorouracil—Anorexia—Methotrexate—testicular cancer	4.09e-05	0.000398	CcSEcCtD
Fluorouracil—Leukopenia—Doxorubicin—testicular cancer	4.07e-05	0.000397	CcSEcCtD
Fluorouracil—Confusional state—Epirubicin—testicular cancer	4.05e-05	0.000394	CcSEcCtD
Fluorouracil—Anaphylactic shock—Epirubicin—testicular cancer	4.01e-05	0.000391	CcSEcCtD
Fluorouracil—Oedema—Epirubicin—testicular cancer	4.01e-05	0.000391	CcSEcCtD
Fluorouracil—Hypotension—Methotrexate—testicular cancer	4.01e-05	0.00039	CcSEcCtD
Fluorouracil—Infection—Epirubicin—testicular cancer	3.99e-05	0.000388	CcSEcCtD
Fluorouracil—Convulsion—Doxorubicin—testicular cancer	3.94e-05	0.000384	CcSEcCtD
Fluorouracil—Nervous system disorder—Epirubicin—testicular cancer	3.94e-05	0.000383	CcSEcCtD
Fluorouracil—Thrombocytopenia—Epirubicin—testicular cancer	3.93e-05	0.000383	CcSEcCtD
Fluorouracil—Tachycardia—Epirubicin—testicular cancer	3.92e-05	0.000381	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Methotrexate—testicular cancer	3.91e-05	0.00038	CcSEcCtD
Fluorouracil—Insomnia—Methotrexate—testicular cancer	3.88e-05	0.000378	CcSEcCtD
Fluorouracil—Myalgia—Doxorubicin—testicular cancer	3.87e-05	0.000377	CcSEcCtD
Fluorouracil—Chest pain—Doxorubicin—testicular cancer	3.87e-05	0.000377	CcSEcCtD
Fluorouracil—Paraesthesia—Methotrexate—testicular cancer	3.85e-05	0.000375	CcSEcCtD
Fluorouracil—Discomfort—Doxorubicin—testicular cancer	3.83e-05	0.000373	CcSEcCtD
Fluorouracil—Anorexia—Epirubicin—testicular cancer	3.83e-05	0.000372	CcSEcCtD
Fluorouracil—Dyspnoea—Methotrexate—testicular cancer	3.82e-05	0.000372	CcSEcCtD
Fluorouracil—Somnolence—Methotrexate—testicular cancer	3.81e-05	0.000371	CcSEcCtD
Fluorouracil—Dyspepsia—Methotrexate—testicular cancer	3.77e-05	0.000368	CcSEcCtD
Fluorouracil—Hypotension—Epirubicin—testicular cancer	3.75e-05	0.000365	CcSEcCtD
Fluorouracil—Confusional state—Doxorubicin—testicular cancer	3.74e-05	0.000365	CcSEcCtD
Fluorouracil—Decreased appetite—Methotrexate—testicular cancer	3.73e-05	0.000363	CcSEcCtD
Fluorouracil—Anaphylactic shock—Doxorubicin—testicular cancer	3.71e-05	0.000362	CcSEcCtD
Fluorouracil—Oedema—Doxorubicin—testicular cancer	3.71e-05	0.000362	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Methotrexate—testicular cancer	3.7e-05	0.00036	CcSEcCtD
Fluorouracil—Infection—Doxorubicin—testicular cancer	3.69e-05	0.000359	CcSEcCtD
Fluorouracil—Pain—Methotrexate—testicular cancer	3.67e-05	0.000357	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Epirubicin—testicular cancer	3.66e-05	0.000356	CcSEcCtD
Fluorouracil—Nervous system disorder—Doxorubicin—testicular cancer	3.64e-05	0.000355	CcSEcCtD
Fluorouracil—Thrombocytopenia—Doxorubicin—testicular cancer	3.64e-05	0.000354	CcSEcCtD
Fluorouracil—Insomnia—Epirubicin—testicular cancer	3.63e-05	0.000353	CcSEcCtD
Fluorouracil—Tachycardia—Doxorubicin—testicular cancer	3.62e-05	0.000353	CcSEcCtD
Fluorouracil—Paraesthesia—Epirubicin—testicular cancer	3.6e-05	0.000351	CcSEcCtD
Fluorouracil—Dyspnoea—Epirubicin—testicular cancer	3.58e-05	0.000348	CcSEcCtD
Fluorouracil—Somnolence—Epirubicin—testicular cancer	3.57e-05	0.000347	CcSEcCtD
Fluorouracil—Anorexia—Doxorubicin—testicular cancer	3.54e-05	0.000345	CcSEcCtD
Fluorouracil—Feeling abnormal—Methotrexate—testicular cancer	3.53e-05	0.000344	CcSEcCtD
Fluorouracil—Dyspepsia—Epirubicin—testicular cancer	3.53e-05	0.000344	CcSEcCtD
Fluorouracil—Decreased appetite—Epirubicin—testicular cancer	3.49e-05	0.00034	CcSEcCtD
Fluorouracil—Hypotension—Doxorubicin—testicular cancer	3.47e-05	0.000338	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Epirubicin—testicular cancer	3.46e-05	0.000337	CcSEcCtD
Fluorouracil—Pain—Epirubicin—testicular cancer	3.43e-05	0.000334	CcSEcCtD
Fluorouracil—Urticaria—Methotrexate—testicular cancer	3.41e-05	0.000332	CcSEcCtD
Fluorouracil—Body temperature increased—Methotrexate—testicular cancer	3.39e-05	0.00033	CcSEcCtD
Fluorouracil—Musculoskeletal discomfort—Doxorubicin—testicular cancer	3.38e-05	0.000329	CcSEcCtD
Fluorouracil—Insomnia—Doxorubicin—testicular cancer	3.36e-05	0.000327	CcSEcCtD
Fluorouracil—SLC22A7—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	3.34e-05	0.0268	CbGpPWpGaD
Fluorouracil—Paraesthesia—Doxorubicin—testicular cancer	3.33e-05	0.000325	CcSEcCtD
Fluorouracil—Dyspnoea—Doxorubicin—testicular cancer	3.31e-05	0.000322	CcSEcCtD
Fluorouracil—Feeling abnormal—Epirubicin—testicular cancer	3.31e-05	0.000322	CcSEcCtD
Fluorouracil—Somnolence—Doxorubicin—testicular cancer	3.3e-05	0.000321	CcSEcCtD
Fluorouracil—Dyspepsia—Doxorubicin—testicular cancer	3.27e-05	0.000318	CcSEcCtD
Fluorouracil—Decreased appetite—Doxorubicin—testicular cancer	3.23e-05	0.000314	CcSEcCtD
Fluorouracil—Gastrointestinal disorder—Doxorubicin—testicular cancer	3.21e-05	0.000312	CcSEcCtD
Fluorouracil—Urticaria—Epirubicin—testicular cancer	3.19e-05	0.00031	CcSEcCtD
Fluorouracil—Pain—Doxorubicin—testicular cancer	3.18e-05	0.000309	CcSEcCtD
Fluorouracil—Body temperature increased—Epirubicin—testicular cancer	3.17e-05	0.000309	CcSEcCtD
Fluorouracil—Hypersensitivity—Methotrexate—testicular cancer	3.16e-05	0.000308	CcSEcCtD
Fluorouracil—Feeling abnormal—Doxorubicin—testicular cancer	3.06e-05	0.000298	CcSEcCtD
Fluorouracil—Pruritus—Methotrexate—testicular cancer	3.03e-05	0.000295	CcSEcCtD
Fluorouracil—SLC29A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	2.98e-05	0.0239	CbGpPWpGaD
Fluorouracil—Hypersensitivity—Epirubicin—testicular cancer	2.96e-05	0.000288	CcSEcCtD
Fluorouracil—Urticaria—Doxorubicin—testicular cancer	2.95e-05	0.000287	CcSEcCtD
Fluorouracil—Body temperature increased—Doxorubicin—testicular cancer	2.94e-05	0.000286	CcSEcCtD
Fluorouracil—Diarrhoea—Methotrexate—testicular cancer	2.93e-05	0.000286	CcSEcCtD
Fluorouracil—CYP2A6—NRF2 pathway—SLC2A6—testicular cancer	2.85e-05	0.0228	CbGpPWpGaD
Fluorouracil—Pruritus—Epirubicin—testicular cancer	2.84e-05	0.000276	CcSEcCtD
Fluorouracil—Dizziness—Methotrexate—testicular cancer	2.84e-05	0.000276	CcSEcCtD
Fluorouracil—Diarrhoea—Epirubicin—testicular cancer	2.75e-05	0.000267	CcSEcCtD
Fluorouracil—Hypersensitivity—Doxorubicin—testicular cancer	2.74e-05	0.000266	CcSEcCtD
Fluorouracil—Vomiting—Methotrexate—testicular cancer	2.73e-05	0.000265	CcSEcCtD
Fluorouracil—Rash—Methotrexate—testicular cancer	2.7e-05	0.000263	CcSEcCtD
Fluorouracil—Dermatitis—Methotrexate—testicular cancer	2.7e-05	0.000263	CcSEcCtD
Fluorouracil—Headache—Methotrexate—testicular cancer	2.69e-05	0.000262	CcSEcCtD
Fluorouracil—Dizziness—Epirubicin—testicular cancer	2.65e-05	0.000258	CcSEcCtD
Fluorouracil—Pruritus—Doxorubicin—testicular cancer	2.63e-05	0.000256	CcSEcCtD
Fluorouracil—Vomiting—Epirubicin—testicular cancer	2.55e-05	0.000248	CcSEcCtD
Fluorouracil—Nausea—Methotrexate—testicular cancer	2.55e-05	0.000248	CcSEcCtD
Fluorouracil—Diarrhoea—Doxorubicin—testicular cancer	2.54e-05	0.000247	CcSEcCtD
Fluorouracil—Rash—Epirubicin—testicular cancer	2.53e-05	0.000246	CcSEcCtD
Fluorouracil—Dermatitis—Epirubicin—testicular cancer	2.53e-05	0.000246	CcSEcCtD
Fluorouracil—Headache—Epirubicin—testicular cancer	2.51e-05	0.000245	CcSEcCtD
Fluorouracil—Dizziness—Doxorubicin—testicular cancer	2.46e-05	0.000239	CcSEcCtD
Fluorouracil—Nausea—Epirubicin—testicular cancer	2.38e-05	0.000232	CcSEcCtD
Fluorouracil—Vomiting—Doxorubicin—testicular cancer	2.36e-05	0.00023	CcSEcCtD
Fluorouracil—Rash—Doxorubicin—testicular cancer	2.34e-05	0.000228	CcSEcCtD
Fluorouracil—Dermatitis—Doxorubicin—testicular cancer	2.34e-05	0.000228	CcSEcCtD
Fluorouracil—Headache—Doxorubicin—testicular cancer	2.33e-05	0.000227	CcSEcCtD
Fluorouracil—Nausea—Doxorubicin—testicular cancer	2.21e-05	0.000215	CcSEcCtD
Fluorouracil—TYMS—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	2.2e-05	0.0177	CbGpPWpGaD
Fluorouracil—ABCC5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.97e-05	0.0158	CbGpPWpGaD
Fluorouracil—SLC22A7—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.7e-05	0.0136	CbGpPWpGaD
Fluorouracil—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	1.66e-05	0.0133	CbGpPWpGaD
Fluorouracil—TYMS—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	1.61e-05	0.0129	CbGpPWpGaD
Fluorouracil—ABCC3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.46e-05	0.0117	CbGpPWpGaD
Fluorouracil—ABCC4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.37e-05	0.011	CbGpPWpGaD
Fluorouracil—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	1.35e-05	0.0108	CbGpPWpGaD
Fluorouracil—UMPS—Metabolism—HPGDS—testicular cancer	1.27e-05	0.0102	CbGpPWpGaD
Fluorouracil—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	1.25e-05	0.01	CbGpPWpGaD
Fluorouracil—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	1.24e-05	0.00991	CbGpPWpGaD
Fluorouracil—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	1.22e-05	0.00976	CbGpPWpGaD
Fluorouracil—UPP2—Metabolism—HPGDS—testicular cancer	1.18e-05	0.00948	CbGpPWpGaD
Fluorouracil—UPP1—Metabolism—HPGDS—testicular cancer	1.18e-05	0.00948	CbGpPWpGaD
Fluorouracil—TYMS—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.17e-05	0.00936	CbGpPWpGaD
Fluorouracil—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	1.16e-05	0.00927	CbGpPWpGaD
Fluorouracil—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1e-05	0.00804	CbGpPWpGaD
Fluorouracil—UMPS—Metabolism—STK11—testicular cancer	9.25e-06	0.00741	CbGpPWpGaD
Fluorouracil—CYP2A6—Biological oxidations—HPGDS—testicular cancer	9.07e-06	0.00726	CbGpPWpGaD
Fluorouracil—UPP2—Metabolism—STK11—testicular cancer	8.6e-06	0.00689	CbGpPWpGaD
Fluorouracil—UPP1—Metabolism—STK11—testicular cancer	8.6e-06	0.00689	CbGpPWpGaD
Fluorouracil—DPYD—Metabolism—HPGDS—testicular cancer	8.2e-06	0.00657	CbGpPWpGaD
Fluorouracil—PPAT—Metabolism—HPGDS—testicular cancer	8.2e-06	0.00657	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle, Mitotic—MAD1L1—testicular cancer	8.16e-06	0.00654	CbGpPWpGaD
Fluorouracil—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	7.36e-06	0.0059	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle—MAD1L1—testicular cancer	7.3e-06	0.00584	CbGpPWpGaD
Fluorouracil—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	6.19e-06	0.00496	CbGpPWpGaD
Fluorouracil—CYP2C8—Biological oxidations—HPGDS—testicular cancer	6.19e-06	0.00496	CbGpPWpGaD
Fluorouracil—PPAT—Metabolism—STK11—testicular cancer	5.96e-06	0.00477	CbGpPWpGaD
Fluorouracil—DPYD—Metabolism—STK11—testicular cancer	5.96e-06	0.00477	CbGpPWpGaD
Fluorouracil—TYMP—Metabolism—HPGDS—testicular cancer	5.85e-06	0.00468	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle, Mitotic—H2AFZ—testicular cancer	5.69e-06	0.00456	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	5.56e-06	0.00445	CbGpPWpGaD
Fluorouracil—TYMS—Cell Cycle—H2AFZ—testicular cancer	5.09e-06	0.00407	CbGpPWpGaD
Fluorouracil—CYP2C9—Biological oxidations—HPGDS—testicular cancer	5.04e-06	0.00404	CbGpPWpGaD
Fluorouracil—CYP1A2—Biological oxidations—HPGDS—testicular cancer	4.31e-06	0.00345	CbGpPWpGaD
Fluorouracil—TYMP—Metabolism—STK11—testicular cancer	4.25e-06	0.0034	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—HPGDS—testicular cancer	3.86e-06	0.00309	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—H2AFZ—testicular cancer	3.37e-06	0.0027	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—HPGDS—testicular cancer	3.36e-06	0.00269	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—KITLG—testicular cancer	3.1e-06	0.00248	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—HPGDS—testicular cancer	2.99e-06	0.0024	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—H2AFZ—testicular cancer	2.93e-06	0.00235	CbGpPWpGaD
Fluorouracil—MTHFR—Metabolism—STK11—testicular cancer	2.8e-06	0.00224	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—KITLG—testicular cancer	2.7e-06	0.00216	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—HPGDS—testicular cancer	2.48e-06	0.00198	CbGpPWpGaD
Fluorouracil—ABCC5—Metabolism—STK11—testicular cancer	2.44e-06	0.00195	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.38e-06	0.0019	CbGpPWpGaD
Fluorouracil—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.36e-06	0.00189	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—FGFR3—testicular cancer	2.3e-06	0.00184	CbGpPWpGaD
Fluorouracil—TYMS—Metabolism—STK11—testicular cancer	2.17e-06	0.00174	CbGpPWpGaD
Fluorouracil—MTHFR—Disease—KIT—testicular cancer	2.11e-06	0.00169	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—FGFR3—testicular cancer	2e-06	0.0016	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.94e-06	0.00155	CbGpPWpGaD
Fluorouracil—ABCC5—Disease—KIT—testicular cancer	1.84e-06	0.00147	CbGpPWpGaD
Fluorouracil—ABCC3—Metabolism—STK11—testicular cancer	1.8e-06	0.00144	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—HPGDS—testicular cancer	1.71e-06	0.00137	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.65e-06	0.00132	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—HPGDS—testicular cancer	1.55e-06	0.00124	CbGpPWpGaD
Fluorouracil—ABCG2—Metabolism—STK11—testicular cancer	1.24e-06	0.000993	CbGpPWpGaD
Fluorouracil—CYP2A6—Metabolism—STK11—testicular cancer	1.13e-06	0.000902	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—HPGDS—testicular cancer	1.06e-06	0.000848	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—HPGDS—testicular cancer	1.05e-06	0.000844	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—HPGDS—testicular cancer	8.62e-07	0.00069	CbGpPWpGaD
Fluorouracil—CYP2C8—Metabolism—STK11—testicular cancer	7.7e-07	0.000616	CbGpPWpGaD
Fluorouracil—ALB—Metabolism—STK11—testicular cancer	7.65e-07	0.000613	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—HPGDS—testicular cancer	7.37e-07	0.00059	CbGpPWpGaD
Fluorouracil—CYP2C9—Metabolism—STK11—testicular cancer	6.26e-07	0.000502	CbGpPWpGaD
Fluorouracil—CYP1A2—Metabolism—STK11—testicular cancer	5.35e-07	0.000429	CbGpPWpGaD
